Spots Global Cancer Trial Database for FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer

Official Title: A Window of Opportunity Study of Taxanes in Head and Neck Cancer

Study ID: NCT06338657

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

Biospecimen Collection

Computed Tomography

Magnetic Resonance Imaging

PEOX-based Polymer Encapsulated Paclitaxel FID-007

Tumor Resection

Study Description

Brief Summary: This phase I trial studies on how the PEOX-based polymer encapsulated paclitaxel FID-007 (FID-007) affects the immune cells around the tumor patients with head and neck squamous cell carcinoma. The active drug in FID-007 is paclitaxel, an established chemotherapy drug that has been shown to kill cancer cells. FID-007 is a packaged form of paclitaxel using a polyethylozaxoline (PEOX) polymer which may allow the drug to reach deeper into tumors and less into normal cells by being smaller. This study is being done to help identify future treatment options and better understand how to improve outcomes of patients with head and neck cancers after surgery.

Detailed Description: PRIMARY OBJECTIVE: I. To describe the phenotypical and functional changes of different T cell subsets within the tumor microenvironment after treatment with FID-007. SECONDARY OBJECTIVES: I. To describe the adverse events associated with neoadjuvant FID-007 prior to surgery for head and neck cancer. II. To evaluate preliminary evidence of efficacy by describing the rate of major and complete pathologic response. III. To describe the rates of locoregional recurrence and rate of distant metastasis at 2 years after surgery. EXPLORATORY OBJECTIVE: I. Explore association between pathologic response and phenotypical and functional changes in T cell subsets. OUTLINE: Patients receive FID-007 intravenously (IV) over 30 minutes once a week for 3 weeks on days 1, 8, and 15 of a single 28 day cycle in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care surgery. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) during screening and blood sample collection throughout the study. After completion of study treatment, patients are followed up every 3 months for 2 years.